2.16
0.00%
+0.00
After Hours:
2.23
0.07
+3.24%
Tff Pharmaceuticals Inc stock is currently priced at $2.16, with a 24-hour trading volume of 15,893.
It has seen a +0.00% increased in the last 24 hours and a -33.34% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.21 pivot point. If it approaches the $1.94 support level, significant changes may occur.
Previous Close:
$2.16
Open:
$2.21
24h Volume:
15,893
Market Cap:
$6.69M
Revenue:
-
Net Income/Loss:
$-21.24M
P/E Ratio:
-3.00
EPS:
-0.72
Net Cash Flow:
$-16.13M
1W Performance:
+10.77%
1M Performance:
-33.34%
6M Performance:
+657.89%
1Y Performance:
+232.31%
Tff Pharmaceuticals Inc Stock (TFFP) Company Profile
Name
Tff Pharmaceuticals Inc
Sector
Industry
Phone
817 438 6168
Address
1751 River Run, Suite 400, Austin
Tff Pharmaceuticals Inc Stock (TFFP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-19-22 | Resumed | H.C. Wainwright | Buy |
Feb-08-21 | Initiated | H.C. Wainwright | Buy |
Dec-07-20 | Initiated | B. Riley Securities | Buy |
Aug-17-20 | Reiterated | Maxim Group | Buy |
Jul-08-20 | Initiated | Maxim Group | Buy |
Tff Pharmaceuticals Inc Stock (TFFP) Latest News
Q2 2024 EPS Estimates for TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Increased by Roth Capital - Defense World
Defense World
Jones Trading cuts TFF Pharmaceuticals shares target on single-product risk - Investing.com South Africa
Investing.com South Africa
TFF Pharmaceuticals reports progress in Phase 2 lung trial - Investing.com
Investing.com
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of ... - GlobeNewswire
GlobeNewswire
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of ... - Yahoo Finance
Yahoo Finance
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates - MSN
MSN
Tff Pharmaceuticals Inc Stock (TFFP) Financials Data
Tff Pharmaceuticals Inc (TFFP) Net Income 2024
TFFP net income (TTM) was -$21.24 million for the quarter ending December 31, 2023, a +33.13% increase year-over-year.
Tff Pharmaceuticals Inc (TFFP) Cash Flow 2024
TFFP recorded a free cash flow (TTM) of -$16.13 million for the quarter ending December 31, 2023, a +44.16% increase year-over-year.
Tff Pharmaceuticals Inc (TFFP) Earnings per Share 2024
TFFP earnings per share (TTM) was -$12.10 for the quarter ending December 31, 2023, a +54.32% growth year-over-year.
Tff Pharmaceuticals Inc Stock (TFFP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Weisman Harlan F | President and CEO |
Aug 15 '23 |
Buy |
0.25 |
600,000 |
150,000 |
814,615 |
Mikhak Zamaneh | Chief Medical Officer |
Aug 15 '23 |
Buy |
0.25 |
120,000 |
30,000 |
135,000 |
MILLS ROBERT S | Director |
Aug 15 '23 |
Buy |
0.25 |
40,000 |
10,000 |
55,980 |
COLEMAN KIRK ALLEN | Chief Financial Officer |
Aug 15 '23 |
Buy |
0.25 |
20,000 |
5,000 |
35,675 |
Roberts Brandi | Director |
Aug 15 '23 |
Buy |
0.25 |
20,000 |
5,000 |
20,000 |
ROCAMBOLI STEPHEN | Director |
Aug 15 '23 |
Buy |
0.25 |
20,000 |
5,000 |
36,000 |
CARLSON CAPITAL L P | 10% Owner |
Aug 15 '23 |
Sale |
0.44 |
215,000 |
94,041 |
5,065,000 |
About Tff Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Cap:
|
Volume (24h):